Lucid Diagnostics Inc. Reports Q2 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests

Reuters

08/13

<a href="https://laohu8.com/S/LUCD">Lucid Diagnostics</a> Inc. Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests

Lucid Diagnostics Inc. has reported its financial results for the second quarter of 2025, ending June 30. The company processed 2,756 EsoGuard® tests in this period, generating revenue of $1.2 million. Lucid's cash and cash equivalents increased to $31.1 million as of June 30, 2025, from $22.4 million at the end of 2024, aided by a Confidentially Marketed Public Offering that resulted in net proceeds of approximately $16.1 million. The company ended the quarter with over $30 million in proforma cash, extending its financial runway beyond upcoming reimbursement milestones. Lucid has scheduled a Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 to discuss the Medicare Local Coverage Determination for EsoGuard.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-011882), on August 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559570604"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559570604\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559570604?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559570604","market":"fut","top_or_hot":-1,"title":"Lucid Diagnostics Inc. Reports Q2 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LUCD\">Lucid Diagnostics</a> Inc. Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LCID\">Lucid</a> Diagnostics Inc. has reported its financial results for the second quarter of 2025, ending June 30. The company processed 2,756 EsoGuard® tests in this period, generating revenue of $1.2 million. Lucid's cash and cash equivalents increased to $31.1 million as of June 30, 2025, from $22.4 million at the end of 2024, aided by a Confidentially Marketed Public Offering that resulted in net proceeds of approximately $16.1 million. The company ended the quarter with over $30 million in proforma cash, extending its financial runway beyond upcoming reimbursement milestones. Lucid has scheduled a Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 to discuss the Medicare Local Coverage Determination for EsoGuard.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-011882), on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid Diagnostics Inc. Reports Q2 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid Diagnostics Inc. Reports Q2 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-13 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LUCD\">Lucid Diagnostics</a> Inc. Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LCID\">Lucid</a> Diagnostics Inc. has reported its financial results for the second quarter of 2025, ending June 30. The company processed 2,756 EsoGuard® tests in this period, generating revenue of $1.2 million. Lucid's cash and cash equivalents increased to $31.1 million as of June 30, 2025, from $22.4 million at the end of 2024, aided by a Confidentially Marketed Public Offering that resulted in net proceeds of approximately $16.1 million. The company ended the quarter with over $30 million in proforma cash, extending its financial runway beyond upcoming reimbursement milestones. Lucid has scheduled a Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 to discuss the Medicare Local Coverage Determination for EsoGuard.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-011882), on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LUCD","symbol_name":"LUCID DIAGNOSTICS INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL8X25vK:1","article_id":"2559570604","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559570604","pubTimestamp":1755086484,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lucid Diagnostics Inc. has reported its financial results for the second quarter of 2025, ending June 30. The company processed 2,756 EsoGuard tests in this period, generating revenue of $1.2 million. Lucid's cash and cash equivalents increased to $31.1 million as of June 30, 2025, from $22.4 million at the end of 2024, aided by a Confidentially Marketed Public Offering that resulted in net proceeds of approximately $16.1 million. The company ended the quarter with over $30 million in proforma cash, extending its financial runway beyond upcoming reimbursement milestones. Lucid has scheduled a Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 to discuss the Medicare Local Coverage Determination for EsoGuard.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LUCD":"LUCID DIAGNOSTICS INC.","PAVM":"PAVmed Inc."},"translate_title":"Lucid Diagnostics Inc.报告2025年第二季度收入为120万美元，处理2,756次EsoGuard测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAVM":0.9,"LUCD":0.9},"content_text":"Lucid Diagnostics Inc. Reports Q2 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests\n    \n\nLucid Diagnostics Inc. has reported its financial results for the second quarter of 2025, ending June 30. The company processed 2,756 EsoGuard® tests in this period, generating revenue of $1.2 million. Lucid's cash and cash equivalents increased to $31.1 million as of June 30, 2025, from $22.4 million at the end of 2024, aided by a Confidentially Marketed Public Offering that resulted in net proceeds of approximately $16.1 million. The company ended the quarter with over $30 million in proforma cash, extending its financial runway beyond upcoming reimbursement milestones. Lucid has scheduled a Multi-Jurisdictional Contractor Advisory Committee meeting on September 4 to discuss the Medicare Local Coverage Determination for EsoGuard.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-011882), on August 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}